Global Pharmerging Markets to Grow at a CAGR of 12.88% During 2017-2021 - AstraZeneca, GlaxoSmithKline, Pfizer, Sanofi, Novartis
The immense growth potential in pharmerging market has driven large multinational pharmaceutical companies to focus on these regions by pursuing organic as well as in-organic routes. To make in-roads into the new geography, the large players usually take in-organic route through strategic expansion initiatives such as acquisitions and alliances. For instance, in December 2015, AstraZeneca entered into a deal with WuXi to acquire its biologics manufacturing facilities in China to expand locally.
View full press release